The first patient receiving focal preventive treatment for vulnerable plaque underwent a 6-month follow-up examination which revealed successful stabilization of the target plaque. The interventional cardiology team which is led by Professor Patrick W. Serruys, MD, PhD, at Erasmus Medical Center in Rotterdam, placed a vProtect Luminal Shield in the left anterior descending (LAD) coronary artery of the patient. The 64-year-old man is enrolled in SECRITT I. It is a pilot study designed to evaluate the vProtect Luminal Shield as a treatment for vulnerable plaques "silent" atherosclerotic deposits in the coronary arteries which do not produce symptoms until they rupture with potentially fatal consequences. The treated artery to date demonstrated excellent blood flow and healing. The Shield is covered by a thin layer of tissue, incorporating it into the arterial wall as part of the healing process. This is a hallmark of a successful implant and demonstrated that the Shield performed much better than expected from a traditional bare metal stents and comparable to the first generation of drug-eluting stents. Patients enrolled in SECRITT I have been referred to the cath lab for treatment of clinically significant coronary lesions that are treated according to current standards of care. Using a combination of optical imaging techniques and ultrasound, the SECRITT I investigators examine the coronary arteries for signs of additional, non-flow-limiting vulnerable plaques, for which patients would not generally receive treatment. Patients with vulnerable plaques undergo a follow-up diagnostic catheterizations 6 months post-treatment, at which time investigators determine the Shield's impact.